Completed

CNS Control of Human Movement: H215O PET Studies

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Synucleinopathies+16

+ Basal Ganglia Diseases

+ Brain Diseases

See all eligibility criteria
How is the trial designed

Observational
Study Start: March 1992
See protocol details

Summary

Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: March 16, 2021
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 1992

Actual date on which the first participant was enrolled.

The main purpose of the studies presented in this protocol is to investigate the physiology of motor control in health as well as the pathophysiological modifications taking place during disease. To this end, we will investigate changes in regional cerebral blood flow (rCBF) as an index of regional neuronal activity, associated with various motor and sensory tasks using Positron Emission Tomography (PET). The rCBF will be obtained by measuring the distribution of the cerebral radioactivity during emission scans following the intravenous bolus injection of 15O-labeled water. The very short half-life of 15O (2 minutes) allows us to measure rCBF repeatedly under different task conditions (see methodology and experimental procedures). With the comparison between PET scans performed in different conditions, we can detect the specific task-related activated regions. PET images will be coregistered to high resolution Magnetic Resonance Images (MRI) to get more accurate anatomical information regarding the activated areas. The results will be correlated with that from other physiological approaches including Electroencephalography (EEG), Transcranial Magnetic Stimulation (TMS), functional Magnetic Resonance Imaging (fMRI), and Magnetic Resonance Spectroscopy (MRS). These studies should provide new information not only about the executive component of the voluntary movements in humans but also the different organizational aspects of the preparatory processes that control them.

NCT00001324
Principal SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last updated: March 16, 2021
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

510 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

SynucleinopathiesBasal Ganglia DiseasesBrain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesCerebrovascular DisordersNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsVascular DiseasesNeurodegenerative DiseasesParkinsonian DisordersDyskinesiasAtaxiaMovement DisordersParkinson DiseaseTremorStroke

Criteria

Patients with movement disorder and normal volunteers.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, United StatesOpen National Institute of Neurological Disorders and Stroke (NINDS) in Google Maps
CompletedOne Study Center